AXLRx Book a call Commission

Twenty minutes with a consultant, before anything is commissioned.Book a scoping call →

Library

The AXLRx analysis library.

Every page is engine output you can read in full before you commission your own.

316 analyses
21 indications
10 analysis types
5 markets

Oncology

NSCLC

6

Competitive IntelligenceUS
Disease LandscapeUS
Patient Flow ModelUS
Payer & HTAUS
Field-Force StrategyUS
Launch ReadinessUS

Metabolic

MASH

5

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS
Market Sizing ModelUS

Rare Disease

PNH

39

Competitive IntelligenceUS GCC FR UK DE
Disease LandscapeUS UK FR GCC DE
Patient Flow ModelUS UK FR GCC DE
Payer & HTAUS FR GCC UK DE
Launch ReadinessUS FR GCC UK DE
KOL MappingUK FR GCC
Pricing Strategy ModelUS DE UK GCC FR
Market Sizing ModelUS FR DE UK GCC
HTA Strategy ModelUK

Immunology

Atopic Dermatitis

4

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS

Metabolic

Type 2 Diabetes

6

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS
Pricing Strategy ModelUS
Market Sizing ModelUS

Metabolic

Obesity

5

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS
Pricing Strategy ModelUS

Neurology

Alzheimer's Disease

4

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS

Rare Disease

IgA Nephropathy

24

Competitive IntelligenceUS GCC UK
Disease LandscapeUS UK GCC
Patient Flow ModelUS GCC UK
Payer & HTAUS UK GCC
Launch ReadinessUS UK GCC
KOL MappingUK GCC
Pricing Strategy ModelUS UK GCC
Market Sizing ModelUS GCC UK
HTA Strategy ModelUK

Rare Disease

Hereditary Angioedema

24

Competitive IntelligenceUS GCC UK
Disease LandscapeUS UK GCC
Patient Flow ModelUS GCC UK
Payer & HTAUS GCC UK
Launch ReadinessUS UK GCC
KOL MappingGCC UK
Pricing Strategy ModelUS UK GCC
Market Sizing ModelUS UK GCC
HTA Strategy ModelUK

Rare Disease

ATTR Amyloidosis

24

Competitive IntelligenceUS UK GCC
Disease LandscapeUS UK GCC
Patient Flow ModelUS GCC UK
Payer & HTAUS UK GCC
Launch ReadinessUS GCC UK
KOL MappingUK GCC
Pricing Strategy ModelUS UK GCC
Market Sizing ModelUS UK GCC
HTA Strategy ModelUK

Rare Disease

Myasthenia Gravis

24

Competitive IntelligenceUS GCC UK
Disease LandscapeUS UK GCC
Patient Flow ModelUS GCC UK
Payer & HTAUS GCC UK
Launch ReadinessUS UK GCC
KOL MappingGCC UK
Pricing Strategy ModelUS UK GCC
Market Sizing ModelUS UK GCC
HTA Strategy ModelUK

Rare Disease

Dravet Syndrome

24

Competitive IntelligenceUS GCC UK
Disease LandscapeUS GCC UK
Patient Flow ModelUS GCC UK
Payer & HTAUS UK GCC
Launch ReadinessUS UK GCC
KOL MappingGCC UK
Pricing Strategy ModelUS GCC UK
Market Sizing ModelUS GCC UK
HTA Strategy ModelUK

Rare Disease

Pompe Disease

24

Competitive IntelligenceUS GCC UK
Disease LandscapeUS UK GCC
Patient Flow ModelUS UK GCC
Payer & HTAUS UK GCC
Launch ReadinessUS UK GCC
KOL MappingGCC UK
Pricing Strategy ModelUS UK GCC
Market Sizing ModelUS GCC UK
HTA Strategy ModelUK

Rare Disease

Fabry Disease

24

Competitive IntelligenceUS GCC UK
Disease LandscapeUS GCC UK
Patient Flow ModelUS UK GCC
Payer & HTAUS GCC UK
Launch ReadinessUS UK GCC
KOL MappingGCC UK
Pricing Strategy ModelUS UK GCC
Market Sizing ModelUS UK GCC
HTA Strategy ModelUK

Rare Disease

Spinal Muscular Atrophy

24

Competitive IntelligenceUS GCC UK
Disease LandscapeUS UK GCC
Patient Flow ModelUS GCC UK
Payer & HTAUS UK GCC
Launch ReadinessUS GCC UK
KOL MappingUK GCC
Pricing Strategy ModelUS UK GCC
Market Sizing ModelUS UK GCC
HTA Strategy ModelUK

Rare Disease

Sickle Cell Disease

24

Competitive IntelligenceUS GCC UK
Disease LandscapeUS UK GCC
Patient Flow ModelUS UK GCC
Payer & HTAUS GCC UK
Launch ReadinessUS GCC UK
KOL MappingUK GCC
Pricing Strategy ModelUS UK GCC
Market Sizing ModelUS GCC UK
HTA Strategy ModelUK

Rare Disease

Gaucher Disease

6

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS
Pricing Strategy ModelUS
Market Sizing ModelUS

Rare Disease

Cold Agglutinin Disease

6

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS
Pricing Strategy ModelUS
Market Sizing ModelUS

Oncology

Breast Cancer HR+/HER2-

10

Competitive IntelligenceUS
Disease LandscapeUS
Patient Flow ModelUS
Payer & HTAUS
Launch ReadinessUS
KOL MappingUS UK
Pricing Strategy ModelUS
Market Sizing ModelUS
HTA Strategy ModelUK

Pulmonology

COPD

4

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS

Immunology

Plaque Psoriasis

5

Competitive IntelligenceUS
Disease LandscapeUS
Payer & HTAUS
Launch ReadinessUS
Pricing Strategy ModelUS